Jiří Kettner

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection

Ryan Zarychanski, Tammy L. Stuart, Steve Doucette et al. · Canadian Medical Association Journal · 2010 · 270 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +7

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study

Gilles Montalescot, Bertram Pitt, Esteban López de Sá et al. · European Heart Journal · 2014 · 183 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

AHEAD score — Long-term risk classification in acute heart failure

Jindřich Špinar, Jiří Jarkovský, Lenka Špinarová et al. · International Journal of Cardiology · 2015 · 93 citations

Medicine, Cardiology, Internal Medicine +14